The net profit exceeded 2 billion for the first time, and the sales volume of Baiyunshan "Jinge" and other three products increased by more than 30%

[China Pharmaceutical network enterprise news] recently, Baiyunshan, the integrator of Nanpai traditional Chinese medicine, released its 2017 annual report According to the data, in 2017, the company achieved an operating revenue of 20.954 billion yuan, an increase of 4.58% year-on-year, and its net profit exceeded 2 billion yuan, an increase of more than 30% The sales volume of five of the 10 main products increased compared with that of last year, among which the sales volume growth rate of "Jinge", "Shujin Jianyao pill" and "huatuozaiban pill" was 52.25%, 30.05% and 63.09% The performance in 2017 is brilliant What's the plan of Baiyunshan in 2018? The first net profit is over 2 billion yuan, and the growth rate of "Da Nan Yao" is fast 1: the performance of Baiyunshan in 2014-2017 (unit: 100 million yuan) (data source: annual report of listed companies) Baiyunshan's operating revenue has been squeezed into the 20 billion echelon in 2016, and the company's operating revenue has been realized in 2017 20.954 billion yuan, up 4.58% year on year In the past three years, the company's net profit has remained above 1 billion yuan, and exceeded the 2 billion yuan threshold in 2017, with an increase of more than 30% Baiyunshan mentioned in the annual report that the main reason for the growth of business income is to actively promote the business development of four major sectors, namely, Dayan pharmaceutical, dahealth, big business and big medical treatment, vigorously build product brands and enterprise brands, and strive to improve quality and efficiency Table 1: revenue of Baiyunshan's main business in 2017 (unit: RMB 100 million) (data source: annual report of listed companies) There are 3 kinds of national traditional Chinese medicine protection and 54 kinds of traditional Chinese medicine production in the south medicine plate of Baiyun Mountain The main products of traditional Chinese medicine include Xiaoke pill, Huatuozaizao pill, compound danshen tablet series, Banlangen Granule Series, Qingkailing series, Angongniuhuang pill, Zishenyutai pill, Shujin Jianyao pill, Xiaochaihu granule, Baoji series, Xiasangju granule, zhufengtougu pill, etc The pharmaceutical products include cefathiamidine, cefixime, amoxicillin, sildenafil citrate ("Jinge"), etc The big health sector is mainly engaged in the production, R & D and sales of beverages, food, health products, cosmetics and other products, including Wang Laoji herbal tea, Ganoderma lucidum spore oil capsule, throat moistening sugar, Guiling cream and so on The large business sector includes wholesale, retail and import and export business of medical products, medical devices, health products, etc In terms of wholesale business, it is mainly carried out through the company's joint venture pharmaceutical company, its holding subsidiary Caizhilin pharmaceutical industry and pharmaceutical import and export company; in terms of retail business, it is mainly carried out through the "Caizhilin" pharmaceutical chain store, "Jianmin" pharmaceutical chain store and yingbang pharmacy and other terminals Through new construction, joint venture, cooperation and other ways, the large medical sector focuses on the development of medical services, traditional Chinese medicine health care, modern elderly care and medical equipment industry At present, the large medical sector is in the stage of layout and investment expansion Sales volume of three major products increased by more than 30% Table 2: sales volume of main products in Baiyunshan in 2017 (data source: annual report of listed companies) Figure 2: market share change of sildenafil citrate in China's urban retail drugstores in 2015-2016 (data source: minernet China's urban retail drugstore terminal competition pattern) Sildenafil citrate tablets produced by Baiyunshan are called Jinge, which is a urinary system medicine and is suitable for the treatment of erectile dysfunction (ED) The main sales market of sildenafil citrate tablets is in the terminal of Chinese urban retail drugstores, with the sales volume of more than 1.7 billion yuan in 2016 The main competitors of this product are Pfizer and Baiyunshan Pharmaceutical General Factory In recent two years, Pfizer's market share has been gradually seized by domestic pharmaceutical companies, and Baiyunshan's market share rose to 35.95% in 2016 According to the data in the annual report, the sales volume of sildenafil citrate tablets in Baiyunshan increased by 52.25% year on year in 2017, mainly because the enterprise vigorously developed new products and launched them to expand the market, and promoted the promotion means to drive the growth of terminal sales volume On May 23, 2017, Baiyunshan announced that the company's products of sildenafil citrate tablets 25mg and 0.1g have obtained the approval documents for supplementary drug application, further enriching the specifications of the products, optimizing the product structure of the company, and helping to improve the sales volume of the products Figure 3: Sales of Shujin Jianyao pill in China's urban retail drugstore terminals from 2015 to 2016 (unit: 10000 yuan) (data source: minernet China's urban retail drugstore terminal competition pattern) Shujin Jianyao pill has the effects of tonifying liver and kidney, strengthening muscles and bones, expelling wind and dehumidification, activating collaterals and relieving pain This product is the product of Guangzhou Baiyunshan chenliji Pharmaceutical Co., Ltd It is an OTC class a product The main sales market is in the terminal of Chinese urban retail drugstore In 2016, the sales volume is close to 1.3 billion yuan According to the data in the annual report, the sales volume of Shujin Jianyao pill in Baiyunshan increased by 30.05% year on year in 2017, mainly due to strengthening the management of advertising and publicity, and doing a good job in the promotion and publicity of drugstore terminals, resulting in the increase of sales volume Figure 4: Sales of huatuozaiban in China's public medical institutions in 2015-2016 (unit: 10000 yuan) (data source: China's public medical institutions terminal competition pattern) Hua Tuo zaizao pill has the functions of removing blood stasis, phlegm and collaterals, promoting qi and relieving pain This product is a product of Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., a basic medicine and national medical insurance category a the sales of this product in China's public medical institutions terminal in 2016 exceeded 200 million yuan, and the sales of retail drugstores terminal in China's cities also exceeded 70 million yuan According to the data in the annual report, the sales volume of huayuozaizaiwan in Baiyunshan increased by 63.09% year-on-year in 2017, mainly due to the increase in the sales volume of the chain business In 2017, the sales volume of cefathiamidine for injection decreased by 36.31% year-on-year, mainly due to the requirements of drug sensitivity test in the 2017 version of the national medical insurance drug catalog and the impact of the outpatient anti drug policy of limiting transfusion The sales volume of Zishenyutai pill decreased by 37.77% year on year The main reason was that the product was gradually replaced from 60g to 30g After the replacement, the unit price increased, and it was necessary to re bid or hang the net, and the medical institutions replaced and re used the medicine, resulting in the short-term impact on the sales volume 2018: eight initiatives, innovation efficiency Baiyunshan mentioned in the annual report that 2018 is the key year for the group to implement the 13th five year plan, and also the "innovation efficiency year" of the group The following eight work will be carried out solidly: Taking "big varieties" as the starting point, we will promote the revitalization and development of South China Pharmaceutical Industry: we will strengthen the collection and analysis of big data on key varieties, cultivate key varieties, and focus on advantageous resources to create "varieties"; we will strengthen brand building and brand management, focus on consolidation and innovation, increase brand investment and promotion in China and China, and further enhance the popularity and reputation of brands and products; Vigorously create "fashionable Chinese medicine", take fashion as the guide, innovation as the starting point, promote the construction of "four modernizations" of traditional Chinese medicine; accelerate the marketing integration, promote the transformation of marketing mode, and create the marketing advantages of Southern medicine With "category diversity" as the core, promote the breakthrough and development of big health sector: implement the differentiated regional strategy, implement the diversified category strategy, and form a big health product system with "one core diversity and category diversity"; implement the publicity strategy, continue to increase investment in related fields, and promote the popularization of Wang Laoji's products; Accelerate the implementation and construction of Wanglaoji museum projects, further enhance the influence of Wanglaoji brand; implement the international expansion strategy, increase product export and overseas market layout; implement the modern science and technology strategy, strengthen the functional research, product quality improvement, new product development and other scientific research work of Wanglaoji and other products Promote the expansion and development of large commercial sectors with the main line of "deep cultivation + development": accelerate the development of modern pharmaceutical logistics extension services, continue to expand the business of hospitals and medical institutions at all levels, and launch the brand of smart pharmacy; accelerate the sinking of terminal distribution business network and the expansion and layout of retail business, and consolidate the network system of hospitals at all levels; Steadily promote the integration of resources between the group's manufacturing enterprises and trading enterprises We will continue to promote the upgrading of Baiyunshan hospital in Guangzhou, strengthen cooperation with professional and medical institutions, and gradually expand this field through international cooperation, M & A, equity participation and other ways to open up new business forms of medical devices To implement innovation driven and promote high-quality development of innovation system: to promote scientific and technological innovation, to build a R & D model based on innovation and combination of imitation and innovation; to promote technological innovation, to build a more effective quality system; to promote management innovation, to build an information-based, standardized and scientific management system We should actively promote the construction of industrial innovation incubators and innovation and entrepreneurship platforms, accelerate the implementation of mass entrepreneurship projects, explore the development models of innovation and entrepreneurship, such as the participation of managers and internal innovation and entrepreneurship, and accelerate the construction of institutional mechanisms for internal innovation and entrepreneurship We will accelerate the pace of M & A and the expansion of new businesses and formats, continue to promote investment in M & A projects in four major sectors, and build a distinctive and differentiated medical service industry Scientific planning, overall planning, further optimization of production capacity layout, strengthening the overall management of the group's overall production capacity development, accelerating the construction of production base projects, and promoting the upgrading and development of manufacturing capacity Strictly manage the enterprise, reduce costs and increase efficiency, and improve the quality and efficiency of large management: improve the system and standardize management; control costs, improve centralized procurement, integrate all kinds of resources, strengthen cost control, reduce costs and increase efficiency; further strengthen resource integration, and continue to promote integrated operation step by step and in a planned way; increase efforts to promote information construction and improve efficiency Conclusion In 2018, in the face of the acceleration of medical reform, the implementation and promotion of a series of new policies, such as pilot drug centralized procurement, medical consortia, two vote system, cancellation of drug markup, control of growth rate of medical expenses, restriction of auxiliary drugs, adjustment of medical insurance payment price, and inclination of medical insurance catalog to cost-effective innovative drugs, pharmaceutical enterprises will face more opportunities and challenges Can Baiyunshan continue to take advantage of the policy We'll see if we can continue to win Source: annual report and announcement of listed companies, original title of minenet database: net profit exceeded 2 billion for the first time, sales of Baiyunshan "Jinge" and other three products increased by more than 30%